Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug-Eluting Stent Benefits Do Not Outweigh Price Tag – Lancet Study

This article was originally published in The Gray Sheet

Executive Summary

Drug-eluting stent use could be restricted to certain high-risk patient subgroups until the price of the stents is reduced, according to a cost-effectiveness study presented Sept. 6 at the European Society of Cardiology meeting in Stockholm

You may also be interested in...

Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC

Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus

Drug-Eluting Stents Will Pay Their Own Way According To SIRIUS Cost Study

The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts